临床荟萃
• 专题 • 上一篇 下一篇
出版日期:
发布日期:
通讯作者:
作者简介:
Online:
Published:
Contact:
摘要: 生物制剂是一种选择性针对参与免疫反应或炎症过程的分子或以受体为靶目标的单克隆抗体或天然抑 制分子的重组产物。生物制剂种类繁多,主要针对细胞因子,B细胞和共刺激信号分子,包括:肿瘤坏死因子抑制剂、 抗白细胞介素6(IL-6)受体单克隆抗体和抗CD20单克隆抗体利妥昔单抗等多种药物,主要用于治疗强直性脊柱炎、 类风湿关节炎和系统性红斑狼疮等自身免疫性疾病。生物制剂的使用应关注其安全性,用药前进行结核筛查,除外活 动性感染和肿瘤。生物制剂的减停药问题有待探讨。
关键词: 生物制品, 肿瘤坏死因子类, 关节炎,类风湿, 脊柱炎
Abstract:
Biological agent is a recombinant product that is selectively targeted to the immune response or to the inflammatory process, or to the target of a monoclonal antibody or a natural inhibitor of the target. The biologic drugs have wide variety, the major targets of most biologic therapies are cytokines, B cells and costimulation molecules, including tumor necrosis factor (TNF) inhibitors,antiinterleukin6 receptor monoclonal antibody, antiCD20 antibodies rutximab and other drugs. They are prescribed for the treatment of rheumatoid arthritis, ankylosing spondylitis,systemic lupus erythematosus and other autoimmune disease.The use of biological agents should pay attention to safety. It is necessary to screen tuberculosis and exclude active infections and cancer before the use of biologic agents. Reduction dose or stopping biological drug need to be discussed.
Key words: biological products, tumor necrosis factors, arthritis, rheumatoid; , spondylitis
靳洪涛,高丽霞. 风湿免疫病生物制剂治疗进展[J]. 临床荟萃, doi: 10.3969/j.issn.1004-583X.2016.05.006.
Jin Hongtao, Gao Lixia. Therapeutic advancements of biologic agents in rheumatic disease[J]. Clinical Focus, doi: 10.3969/j.issn.1004-583X.2016.05.006.
导出引用管理器 EndNote|Ris|BibTeX
链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2016.05.006
https://huicui.hebmu.edu.cn/CN/Y2016/V31/I5/490